Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Global Market for Sleep-Wake Disorders, 2005-2012, The Trends, Opportunities, and Insights in a High-Value CNS Therapy Area |
Dec 2005 | £795 | 100% |
| Pipeline Insight: Epilepsy Pipeline drugs struggle to outshine their marketed predecessors |
Oct 2006 | £7,210 | 90% |
| Monoclonal Antibodies Report | Jun 2008 | £4,805 | 86% |
| Antiageing and Life Enhancement Pharmacotherapeutics | Jan 2006 | £795 | 83% |
| Psychopharmacotherapy Market Insights Obstacles & Opportunities in Mood Disorders & Cognitive Impairment, 2005-2012 |
Nov 2005 | £795 | 81% |
| M&A trends in Pharma | Oct 2008 | £7,210 | 79% |
| Stakeholder Opinions: Parkinson\'s Disease Review of Key Commercial Opportunities in the Symptomatic Treatment Market |
Jul 2006 | £1,335 | 77% |
| Commercial Insight: Osteoarthritis Market sees steady growth |
Dec 2006 | £8,365 | 72% |
| Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2nd edition |
Jun 2010 | £1,705 | 72% |
| Biomarkers | Aug 2011 | £3,035 | 72% |
| Personalized Medicine 2010 Assessing the Opportunities and Challenges in Commercializing Companion |
May 2010 | £1,580 | 70% |
| Pipeline Insight: Breakthrough Pain Fast-acting players will capture majority market share |
Nov 2006 | £7,210 | 68% |
| Biomarkers, Tests and Trends for Drug R&D | Feb 2010 | £1,390 | 67% |
| Biobanking: Technologies and Global Markets | Jun 2011 | £3,065 | 67% |
| Reformulation Strategies Comparisons of Past and Future Reformulation Strategies |
Sep 2006 | £4,805 | 66% |
| Commercial Insight: Antipsychotics Revenues of depots and new agents will partially offset generic erosion |
Oct 2009 | £9,615 | 65% |
| Global Regenerative Medicine Market | Dec 2011 | £760 | 63% |
| Stakeholder Opinions: Primary Brain Cancer | Jul 2007 | £2,400 | 61% |
| Allergan Inc. PharmaVitae Profile | Dec 2008 | £3,605 | 60% |
| Biomarkers: Technological and Commercial Outlook 2011-2021 discovering the pharma and diagnostics opportunities |
Jun 2011 | £1,499 | 59% |
| Wyeth: PharmaVitae Profile | Mar 2009 | £3,605 | 57% |
| Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
Nov 2006 | £7,210 | 57% |
| Stakeholder Opinions: Diagnostics in Neurology Predictive Biomarkers Expand Drug Revenues |
Jul 2008 | £2,400 | 55% |
| New Drug Futures 2009 | Jan 2012 | £1,995 | 54% |
| Monoclonal Antibodies Report Part I | Jun 2007 | £4,805 | 54% |
| New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency | May 2009 | £3,605 | 53% |
| Nanotechnology: Players, products & prospects to 2018 (Volume II) | Jan 2012 | £595 | 52% |
| Vaccines Market Insight Products, Pipelines & Market Outlook |
Jan 2007 | £1,095 | 48% |
| Advanced Oral & Parenteral Drug Delivery Technologies Players, Products & Prospects to 2015 |
Jan 2011 | £995 | 48% |
| Biobanking: Technologies A Global Market Watch, 2009-2015 |
Nov 2011 | £2,125 | 47% |
